Literature DB >> 12679734

The effect of Taurolidine on adherent and floating subpopulations of melanoma cells.

D P Shrayer1, H Lukoff, T King, P Calabresi.   

Abstract

The annual incidence of malignant melanoma is estimated at 10-12 per 100000 inhabitants in countries of Central Europe and the US, with more recent estimates showing a dramatic upward trend. Taurolidine (Carter/Wallace, Cranberry, NJ) is a novel, potentially effective, antitumor chemotherapeutic agent. We hypothesized that Taurolidine could inhibit the growth, induce apoptosis, affect the cell cycle and change morphology of melanoma cells. We expected this process to be different in adherent and floating subpopulations that may be reflective of solid tumors and their metastases. Analysis of MNT-1 human and B16F10 murine melanoma cells showed that at 72 h the IC(50) of Taurolidine was 25.4+/-3.3 microM for MNT-1 human melanoma cells and 30.9+/-3.6 microM for B16F10 murine melanoma cells. Taurolidine induced DNA fragmentation of melanoma cells in a dose-dependent manner. Taurolidine (75 and 100 microM) induced 52-97% Annexin-V binding (apoptosis), respectively. Evaluation of cell cycle after 72 h exposure to Taurolidine (0-100 microM) revealed that the percentage of melanoma cells in S phase increased from 27 to 40% in the adherent subpopulation and from 33 to 49% in the floating subpopulation. Phase contrast microscopy revealed a marked swelling of melanoma cells and decreasing cell numbers in adherent subpopulation starting at 24 h with 25 microM Taurolidine. Shrinkage of cells dominated at 75-100 microM Taurolidine. Using Cytospin assay in the floating population, we observed swelling of melanoma cells induced by 25-100 micro Taurolidine and appearance of giant (multinuclear) forms resulting from exposure to 75-100 micro Taurolidine. Some floating cells with normal morphology were observed with low concentrations of Taurolidine (0-25 microM). These data show that effects of Taurolidine may be different in adherent and floating subpopulations of melanoma cells. More importantly, floating subpopulations that may contain some viable melanoma cells, may be reflective of potential metastasis after treatment of solid tumors in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12679734     DOI: 10.1097/00001813-200304000-00007

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  9 in total

1.  Effects of increasing doses of a bolus injection and an intravenous long-term therapy of taurolidine on subcutaneous (metastatic) tumor growth in rats.

Authors:  Chris Braumann; Marco Schoenbeck; Charalambos Menenakos; Maik Kilian; Christoph A Jacobi
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

2.  Impact of taurolidine on the growth of CC531 coloncarcinoma cells in vitro and in a laparoscopic animal model in rats.

Authors:  G Nestler; H U Schulz; D Schubert; S Krüger; H Lippert; M Pross
Journal:  Surg Endosc       Date:  2004-12-09       Impact factor: 4.584

3.  Co-immunotherapy with interleukin-2 and taurolidine for progressive metastatic melanoma.

Authors:  G C O'Brien; R A Cahill; D J Bouchier-Hayes; H P Redmond
Journal:  Ir J Med Sci       Date:  2006 Jan-Mar       Impact factor: 1.568

4.  Taurolidine antiadhesive properties on interaction with E. coli; its transformation in biological environment and interaction with bacteria cell wall.

Authors:  Francesco Caruso; James W Darnowski; Cristian Opazo; Alexander Goldberg; Nina Kishore; Elin S Agoston; Miriam Rossi
Journal:  PLoS One       Date:  2010-01-28       Impact factor: 3.240

5.  Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines.

Authors:  Denise K Walters; Roman Muff; Bettina Langsam; Philipp Gruber; Walter Born; Bruno Fuchs
Journal:  Invest New Drugs       Date:  2007-04-26       Impact factor: 3.850

6.  Taurolidine induces epithelial-mesenchymal transition via up-regulation of the transcription factor Snail in human pancreatic cancer cell lines.

Authors:  Birgit Hotz; Ulrike Erben; Marco Arndt; Heinz J Buhr; Hubert G Hotz
Journal:  Int J Colorectal Dis       Date:  2014-09-03       Impact factor: 2.571

7.  Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case.

Authors:  Chris Braumann; Goetz Winkler; Patrick Rogalla; Charalambos Menenakos; Christoph A Jacobi
Journal:  World J Surg Oncol       Date:  2006-06-24       Impact factor: 2.754

8.  Taurolidine cooperates with antineoplastic drugs in neuroblastoma cells.

Authors:  Georg Eschenburg; Christian Luckert; Konrad Reinshagen; Robert Bergholz
Journal:  Genes Cancer       Date:  2014-11

9.  Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma - in vitro and in vivo.

Authors:  M Buchholz; B Majchrzak-Stiller; S Hahn; D Vangala; R W Pfirrmann; W Uhl; C Braumann; A M Chromik
Journal:  BMC Cancer       Date:  2017-03-24       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.